Comparative Pharmacology
Head-to-head clinical analysis: CENESTIN versus ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENESTIN versus ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL.
CENESTIN vs ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription and exerting effects on reproductive tissues, bone, cardiovascular system, and CNS.
Combination hormonal contraceptive: ethynodiol diacetate is a progestin that suppresses gonadotropin secretion (LH and FSH) via negative feedback on the hypothalamic-pituitary axis, inhibiting ovulation; ethinyl estradiol is an estrogen that stabilizes the endometrium and increases cervical mucus viscosity, impeding sperm penetration.
0.45 mg orally once daily; titrate up to 1.25 mg once daily based on symptoms. Maximum dose 1.25 mg/day.
1 tablet (1 mg ethynodiol diacetate / 35 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo days.
None Documented
None Documented
Terminal elimination half-life is approximately 10-24 hours for conjugated estrogens; this long half-life allows for once-daily dosing and sustained estrogenic effects.
Ethynodiol diacetate: 12-14 hours; ethinyl estradiol: 13-27 hours (mean ~17 hours). Steady-state achieved after 3-4 days.
Primarily renal, with approximately 90% excreted in urine as glucuronide and sulfate conjugates; about 10% excreted in feces via bile.
Renal (approximately 40% as metabolites), fecal (approximately 60% as metabolites). Ethynodiol diacetate is extensively metabolized; less than 1% excreted unchanged.
Category C
Category D/X
Estrogen
Estrogen